The phase 2, single-arm (adaptive-trial), open-label APTITUDE trial evaluated the efficacy and safety of the fully humanized anti-interleukin (IL)-6R antibody, tocilizumab, with MTX in anti-TNF refractory JIA-uveitis. Here, TNF is linked to uveitis.